EndoPredict outperforms Oncotype Dx in predicting the risk breast cancer recurrence

Data being presented at the 2016 San Antonio Breast Cancer Symposium show Myriad’s EndoPredict, a second-generation test, significantly outperformed Oncotype Dx, a first-generation test, in predicting the long-term recurrence of breast cancer, particularly in years five to 10 following surgery. Clinicians can consider using EndoPredict to identify patients who can forgo chemotherapy with confidence, knowing they have a low risk of recurrence over 10 years.
Go to Source